Pharmacy - Emergency Medicine Deep Dive Podcast

When a patient arrives in the emergency department in a state of extreme agitation or excited delirium, every second counts. In this episode, we explore the growing use of ketamine as a rapid intervention to control dangerous psychomotor agitation when traditional sedatives may act too slowly. Research shows ketamine can achieve adequate sedation far faster than medications like haloperidol, lorazepam, or midazolam, helping protect both patients and medical teams in high risk situations. But speed comes with tradeoffs, including a higher risk of complications such as hypoxia and the possible need for airway support. We unpack what the literature says about when ketamine may be appropriate and why careful cardiopulmonary monitoring is essential. Join us as we examine how clinicians balance urgency, safety, and evidence when managing one of the most challenging emergencies in acute care.

In this episode, we unpack the 2025 ACLS medication updates from the American Heart Association and what they mean for real-world cardiac arrest care. Epinephrine remains the standard for improving short-term survival, but evidence is still limited when it comes to long-term neurological outcomes. Alternative vasopressors and high-dose strategies show no clear advantage and routine use of calcium, sodium bicarbonate, and magnesium is not recommended. We also explore the nuanced role of amiodarone and lidocaine in select shockable arrests. Above all, the guidelines reinforce what saves lives most: rapid defibrillation, high-quality CPR, and getting the basics right.

The fever persists but does that mean treatment is failing? Not necessarily. In this episode we unpack why ongoing fevers do not automatically signal the need to escalate antibiotics. Instead, smart stewardship focuses on the bigger picture including hemodynamic stability, improving organ function, and microbiologic data that reveal the true course of infection. You will learn how to interpret persistent fevers, avoid unnecessary drug toxicity, and make informed decisions that fight antibiotic resistance all without overreacting to the thermometer.

Drug resistant status epilepticus and seizures are some of the highest stakes emergencies in the ED. In this episode, we explore the ketogenic diet as an emerging strategy for patients who continue seizing despite standard therapy. We highlight how quickly seizure control can be achieved, why early initiation in critically ill patients is gaining attention, and how this therapy is starting to influence acute care decision making. Tune in to see how a traditionally outpatient therapy is stepping into the ED and ICU playbook for bedside seizure management.

Status epilepticus is a true neurologic emergency where every minute matters. In this episode, we review modern emergency management strategies, starting with benzodiazepines as first line therapy and examining why traditional second line agents like levetiracetam often fall short in rapidly stopping seizures. We explore growing evidence supporting the early use of ketamine, highlighting its ability to terminate refractory seizures while maintaining hemodynamic stability and often avoiding immediate intubation. The discussion emphasizes the importance of adequate early dosing and decisive escalation to prevent long term neurologic injury. Ultimately, this episode makes the case for faster, more aggressive intervention to achieve seizure control within the critical first thirty minutes.

Rate control has long been the default strategy for atrial fibrillation, reserving rhythm control primarily for symptom management. In this episode, we examine the EAST-AFNET 4 trial and the evidence supporting early rhythm control as a means to reduce stroke and cardiovascular death in patients diagnosed within the past year. We discuss how timely initiation of anti arrhythmic therapy or catheter ablation differs fundamentally from delayed rhythm strategies studied in earlier trials. The episode explores why these findings challenge longstanding practice patterns and how they may redefine standard care for newly diagnosed atrial fibrillation, even in minimally symptomatic patients.

Heart failure looks better on paper but is it really gone? In this episode, we explore the landmark TRED HF trial and why a recovered ejection fraction in dilated cardiomyopathy often represents remission rather than cure. Nearly 40% of patients relapsed within six months of stopping therapy, and that risk rose to 65% over five years, sometimes even after medications were restarted at lower doses. We discuss why cardiac imaging and biomarkers still cannot reliably identify who can safely stop treatment. The message is clear: for most patients, continuing guideline directed medical therapy (GDMT) remains essential to protect the heart and prevent relapse.

In this episode, we explore the potential of ketamine as a neuroprotective therapy for patients recovering from cardiac arrest. Brain injury after arrest often follows a “two-hit” process of ischemia and reperfusion, triggering toxic chemical cascades that damage neurons. As an NMDA receptor antagonist, ketamine may interrupt these pathways and help preserve cognitive function. While animal studies show promise, human clinical trials in this population are still lacking. We also discuss how modern evidence challenges old concerns about ketamine and intracranial pressure, highlighting the need for future research on its role in post-arrest neurological outcomes.

This episode explores the emergence of medetomidine, a powerful veterinary sedative, now appearing in the illicit opioid supply and rapidly replacing xylazine across various regions of the United States and Canada. Clinicians are reporting a severe and unfamiliar withdrawal syndrome marked by extreme hypertension, rapid heart rate, and persistent vomiting, often requiring ICU care and resisting standard treatments. We explore how prolonged sedation complicates naloxone reversals, why standard opioid withdrawal treatments frequently fail, and how targeted alpha-2 agonists like dexmedetomidine are emerging as effective stabilization tools. The discussion highlights the urgent need for expanded toxicology screening and updated emergency and public health protocols as the polysubstance crisis continues to evolve.

When managing atrial fibrillation, clinicians face a pivotal choice...control the heart rate or restore normal rhythm. In this episode, we explore emerging evidence showing that for patients with long standing atrial fibrillation, neither strategy clearly outperforms the other in overall cardiovascular outcomes. However, timing changes everything. For patients diagnosed within the past year, early rhythm control can significantly reduce the risk of stroke and cardiac related death. Join us as we break down why the age of the condition, not just the treatment option, should guide clinical decision making.

In this episode, we dive into the RSI Trial, a groundbreaking study comparing ketamine and etomidate for rapid sequence intubation in critically ill adults. While the trial found no difference in 28-day mortality between the two drugs, it revealed that ketamine was linked to more episodes of cardiovascular collapse, largely due to increased vasopressor use. We unpack the clinical debate around this finding, exploring whether it reflects true hemodynamic instability or the effects of ketamine’s stronger analgesia. Tune in as we explore what this means for critical care practice and challenge the assumption that ketamine is always the safer choice.

When patients arrive with acute decompensated heart failure, IV antibiotics are often started “just in case.” But what if that precaution is doing more harm than good? In this episode, we break down new research showing that unnecessary IV antibiotics, packed with extra fluid and surprising amounts of sodium, can worsen outcomes, extend hospital stays, and even increase readmissions. We explore why these effects happen, what the data reveals, and how smarter antimicrobial stewardship can protect vulnerable heart-failure patients. Tune in to learn why sometimes less treatment truly means better care!

Dive into the complex world of lithium management as we explore how the drug is processed in the body, how common medications affect its levels, and the risks of chronic exposure. We unpack SILENT syndrome, a serious form of long term neurotoxicity, and challenge conventional wisdom around dialysis for lithium toxicity. Discover why careful monitoring and hydration may be safer than rapid intervention and what the latest research says about protecting the brain.

Renal drug dosing is more complex than most clinicians expect. This episode examines why common creatinine based measures such as creatinine clearance and estimated glomerular filtration rate can be misleading, from the biological limitations of creatinine to the risks of applying the wrong calculation to the wrong medication. These inaccuracies can have real clinical consequences, particularly for drugs that demand precise dosing. We discuss the practical challenges clinicians face, including inconsistent guideline use and the limited availability of dosing recommendations based on estimated glomerular filtration rate. The episode highlights how thoughtful clinical judgment, evidence informed resources, and collaboration with pharmacists can help ensure safer and more reliable dosing when kidney function estimates fall short.

In this episode, we explore the growing debate around the role of beta blockers after myocardial infarction, especially for patients who have a preserved or only mildly reduced ejection fraction. Recent studies have challenged the long standing assumption that all post MI patients benefit equally, suggesting that while beta blockers remain essential for those with reduced heart function, their advantage may be far less clear in patients with normal LVEF. We break down the emerging evidence, the nuanced benefits seen in patients with mildly reduced LVEF (40 to 49%), and how clinicians are beginning to shift toward a more individualized, LVEF guided approach to post MI care.

In this episode, we dive into the evolving strategies for treating Pseudomonas aeruginosa infections with piperacillin-tazobactam (PTZ). Challenging the conventional high-dose approach of 4.5g IV every six hours, recent evidence and Monte Carlo simulations suggest that more isn’t always better. For most strains with MICs ≤8 mg/L, the standard 3.375g IV Q6H is usually sufficient, while higher MIC infections (≥16 mg/L) often require extended infusions to maximize the time the drug remains above the MIC (fT>MIC). We break down why time above MIC...not just total dose, is the key to improving clinical outcomes and how this insight is reshaping how we think about optimal PTZ therapy.

In this episode, we dive into the critical role of drug protein binding in pharmacokinetics and why it matters for patient care. Only the unbound, or free, fraction of a drug is pharmacologically active...available for distribution, metabolism, and elimination. We explore how highly protein-bound drugs, often bound to albumin, act as reservoirs, influencing drug half-life and distribution. Changes in protein binding, due to conditions like hypoalbuminemia or drug-drug interactions, can dramatically alter free drug concentrations, risking treatment failure or toxicity. Through real-world case examples involving valproic acid, furosemide, and ceftriaxone, we reveal how understanding protein binding is essential for safe and effective therapy.Some Common Highly Protein-Bound Drugs and Their Approximate Binding Percentages:Anticoagulants:Warfarin (~99% bound)Antiepileptics:Phenytoin (~90–95% bound)Valproic acid (~90–95% bound)Carbamazepine (~75–80% bound)NSAIDs:Naproxen (~99% bound)Diclofenac (~99% bound)Ibuprofen (~99% bound)Cardiovascular drugs:Verapamil (~95% bound)Propafenone (~95% bound)Amiodarone (~96% bound)Furosemide (~95% bound)Antibiotics:Ceftriaxone (~85–95% bound)Erythromycin (~90% bound)Clindamycin (~90% bound)Sulfonamides (Sulfamethoxazole) (~90–95% bound)Ertapenem (~85–95% bound)Psychotropics / Others:Diazepam (~98% bound)Tolbutamide (~96% bound)Clozapine (~95% bound)Fluoxetine (~95% bound)

In this episode, we dive into a critical and controversial aspect of rapid sequence intubation (RSI)...the optimal order of administering rocuronium, a paralytic, and ketamine, a sedative. We explore recent research, including a Monte Carlo analysis that quantifies the risk of anesthetic awareness when rocuronium is given before ketamine, highlighting the chilling possibility of patients being paralyzed yet conscious. We also examine an observational study that suggests giving the paralytic first may modestly reduce apnea time, but with the crucial limitation that patient awareness was not assessed. Through scientific insights and a deeply moving personal account of anesthetic awareness, this episode underscores the urgent need for further research and the high stakes of drug sequencing in critically ill patients.

Managing anticoagulation in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD) is a complex clinical challenge. In this episode, we explore the delicate balance between preventing venous thromboembolism (VTE) and minimizing bleeding risks in this vulnerable population. We discuss the evolving role of direct oral anticoagulants (DOACs), including the limited and often controversial evidence supporting their use in ESRD, alongside the continued relevance of warfarin. Drawing on guideline recommendations, observational studies, and emerging research on novel agents such as Factor XI inhibitors, we highlight the nuances of decision-making and the importance of individualized therapy. Whether you’re a clinician, researcher, or learner, this episode provides a concise yet comprehensive look at where the field stands and where it’s headed.

What if treating diabetic ketoacidosis didn’t always require IV drips, ICU beds, or long hospital stays? In this episode, we explore the SQuID protocol, a cutting-edge approach that uses subcutaneous insulin for mild to moderate DKA. Evidence shows it can safely resolve DKA, speed up recovery, and free up critical hospital resources...all while keeping outcomes comparable to traditional treatment. We’ll also discuss the important limitations, safety considerations, and the steps needed before this approach can be widely adopted. Tune in to hear how SQuID could transform the way we manage DKA.